Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) COO Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72. Following the sale, the chief operating officer owned 182,177 shares of the company’s stock, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Cohlhepp also recently made the following trade(s):
- On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The stock was sold at an average price of $29.00, for a total transaction of $15,544.00.
- On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $20.29, for a total transaction of $253,625.00.
- On Wednesday, April 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The stock was sold at an average price of $23.01, for a total transaction of $287,625.00.
Bicara Therapeutics Stock Performance
NASDAQ BCAX traded down $0.77 on Friday, reaching $28.91. 584,437 shares of the company’s stock traded hands, compared to its average volume of 609,333. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -10.40 and a beta of -0.81. The stock has a 50 day moving average price of $23.27 and a 200-day moving average price of $20.04. Bicara Therapeutics Inc. has a fifty-two week low of $9.47 and a fifty-two week high of $30.99.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on BCAX. Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday, May 24th. Guggenheim initiated coverage on Bicara Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $42.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday. Citizens Jmp restated a “market outperform” rating and issued a $31.00 price objective on shares of Bicara Therapeutics in a research report on Tuesday, March 31st. Finally, Bank of America initiated coverage on shares of Bicara Therapeutics in a research note on Wednesday, March 25th. They set a “buy” rating and a $35.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bicara Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $30.27.
Get Our Latest Report on Bicara Therapeutics
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Bicara Therapeutics by 419.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after purchasing an additional 3,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the 4th quarter valued at about $45,000. Larson Financial Group LLC raised its holdings in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Bicara Therapeutics by 385.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company’s stock worth $97,000 after purchasing an additional 4,585 shares during the period.
Bicara Therapeutics Company Profile
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Read More
- Five stocks we like better than Bicara Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
